{
    "clinical_study": {
        "@rank": "105895", 
        "arm_group": [
            {
                "arm_group_label": "Exposed cohort", 
                "description": "Women with the first day of LMP between 30 days before and 45 days after any Cervarix dose and between 30 days before and 90 days after any Cervarix dose."
            }, 
            {
                "arm_group_label": "Non-exposed cohort", 
                "description": "Women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome)."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the risk of spontaneous abortion during weeks 1-23 and weeks 1-19 of\n      gestation, respectively, and other pregnancy outcomes, in an exposed cohort, i.e. women with\n      last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and\n      90 days after any dose of Cervarix, when compared to a non-exposed cohort, i.e. women with\n      LMP between 120 days and 18 months after the last Cervarix dose. The data collected in the\n      Clinical Practice Research Datalink General Practitioner OnLine Database (CPRD GOLD) in the\n      UK, will be analysed in this study."
        }, 
        "brief_title": "Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Infections, Papillomavirus", 
        "condition_browse": {
            "mesh_term": "Abortion, Spontaneous"
        }, 
        "detailed_description": {
            "textblock": "Convenience sampling will be used in this study. It is planned to include all eligible\n      pregnant women (included in CPRD GOLD and who fulfil to the inclusion/exclusion criteria) in\n      each of the two cohorts."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For the exposed cohort:\n\n        All subjects must satisfy all of the following criteria at entry into the exposed cohort:\n\n          -  Full date of first day of LMP available in the database or calculated from Estimated\n             date of delivery (EDD).\n\n          -  Female, aged between, and including, 15 and 25 years of age at LMP.\n\n          -  Recorded in the CPRD GOLD for at least 12 months at LMP.\n\n          -  First day of LMP available in the database or calculated from EDD  between September\n             1st 2008 and June 30th 2011.\n\n          -  At least one dose of Cervarix received between September 1st 2008 and June 30th 2011.\n\n          -  Full date of Cervarix vaccination(s) available.\n\n          -  First day of LMP available in the database or calculated from EDD between 30 days\n             before and 90 days after any dose of Cervarix.\n\n          -  Subject defined as acceptable in CPRD GOLD.\n\n        For the non-exposed cohort:\n\n        All subjects must satisfy all of the following criteria at entry into the non-exposed\n        cohort:\n\n          -  Full date of first day of LMP available in the database or calculated from EDD.\n\n          -  Female, aged between, and including, 15 and 25 years of age at LMP.\n\n          -  Recorded in the CPRD GOLD since at least 12 months at LMP.\n\n          -  First day of LMP available in the database or calculated from EDD between September\n             1st 2008 and June 30th 2011.\n\n          -  At least one dose of Cervarix received between September 1st 2008 and June 30th 2011.\n\n          -  Full date of Cervarix vaccination(s) available.\n\n          -  First day of LMP available in the database or calculated from EDD between 120 days\n             and 18 months after the last dose of Cervarix.\n\n          -  Subject defined as acceptable in CPRD GOLD.\n\n        Exclusion Criteria:\n\n        For the exposed cohort:\n\n        \u2022  Female with the first day LMP between 30 days before and 90 days after at least one\n        dose of unspecified Human Papillomavirus vaccine and/or Gardasil.\n\n        For the non-exposed cohort:\n\n          -  Female with the first day LMP between 30 days before and 90 days after at least one\n             dose of unspecified Human Papillomavirus vaccine and/or Gardasil.\n\n          -  Female included for a previous pregnancy in the exposed cohort."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "25 Years", 
            "minimum_age": "15 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pregnant women aged 15 to 25 years, residing in UK, exposed to Cervarix and whose data is\n        recorded in the CPRD GOLD."
            }
        }, 
        "enrollment": {
            "#text": "1046", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905462", 
            "org_study_id": "114101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Non-exposed cohort", 
                    "Exposed cohort"
                ], 
                "description": "Analyses of data collected within the CPRD GOLD database.", 
                "intervention_name": "Data Collection", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Non-exposed cohort", 
                    "Exposed cohort"
                ], 
                "description": "Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.", 
                "intervention_name": "Cervarix", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cervarix", 
            "Spontaneous abortion", 
            "Vaccine", 
            "Human Papillomavirus"
        ], 
        "lastchanged_date": "September 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SW1W 9SZ"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "2", 
        "official_title": "Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix in the United Kingdom", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: European Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Occurrence of spontaneous abortion", 
            "safety_issue": "No", 
            "time_frame": "Weeks 1-23 of gestation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Occurrence of spontaneous abortion", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1-19 of gestation"
            }, 
            {
                "description": "Induced/therapeutic and other abortions; Stillbirth; Birth defects identified among all pregnancies with known outcome classified as live births, stillbirths and abortions. For live births, birth defects identified within the first 12 weeks of life will be included; Small/large for gestational age at birth; Pre-term and post-term delivery.", 
                "measure": "Occurrence of other pregnancy outcomes", 
                "safety_issue": "No", 
                "time_frame": "12 months after last menstrual period"
            }, 
            {
                "measure": "Baby's death", 
                "safety_issue": "No", 
                "time_frame": "First 12 weeks of baby's life"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "collaborator": {
                "agency": "Clinical Practice Research Datalink General Practitioner OnLine Database", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}